Accelerated approval was granted to erdafitinib for treating locally advanced or metastatic bladder cancer with genetic alterations FGFR3 or FGFR2 after progressing on chemotherapy. A companion diagnostic was also approved.
FDA Approvals
FDA Okays First Targeted Drug for Metastatic Bladder Cancer
